Healthcare / BiotechnologyShenzhen
$47.11
-0.94 (-1.96%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $416.7M · quality 53.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.1B
P/E
27.1x
↑EV/EBITDA
15.0x
↑ROE
6.2%
↑Gross Margin
92.0%
↑Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-7.0%
FCF CAGR
—
FCF margin
26.5%
FCF / Net income
1.40x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.17B · net income $219.9M · FCF $308.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.17B | $1.17B | $1.43B | $1.58B | $1.45B |
| Net Income | $219.9M | $219.9M | $398.7M | $509.2M | $598.1M |
| EBITDA | $340.2M | $340.2M | $537.6M | $630.3M | $719.6M |
| EPS | 1.69 | 1.69 | 3.03 | 3.81 | 4.46 |
| Gross Margin | 92.0% | 92.0% | 94.2% | 93.5% | 93.6% |
| Operating Margin | 23.4% | 23.4% | 38.5% | 38.8% | 45.7% |
| Net Margin | 18.9% | 18.9% | 27.8% | 32.3% | 41.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.04 | 0.04 | 0.05 | 0.05 | 0.04 |
| Current Ratio | 7.89 | 7.89 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $308.9M | $308.9M | $427.9M | $416.7M | $-224.2M |
| Returns | |||||
| ROE | 6.2% | 6.2% | 11.6% | 14.5% | 19.4% |
| Valuation | |||||
| P/E | 27.07 | 27.07 | 17.10 | 19.53 | 19.65 |
| EV/EBITDA | 15.02 | 15.02 | 11.17 | 14.43 | 15.60 |
| P/B | 1.73 | 1.73 | 1.98 | 2.83 | 3.82 |
| Growth & Yield | |||||
| Revenue Growth | -18.6% | -18.6% | -9.2% | 9.0% | — |
| EPS Growth | -44.1% | -44.1% | -20.5% | -14.7% | — |
| Dividend Yield | 1.0% | 1.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
35.2%
EPS terminal req.
$4.18
Spread vs growth
-79.3%
5Y implied EPS CAGR
24.5%
EPS terminal req.
$5.06
Spread vs growth
-68.6%
10Y implied EPS CAGR
17.0%
EPS terminal req.
$8.15
Spread vs growth
-61.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-13.2%
Start / end P/E
18.1x → 27.8x
EPS bridge
3.03 → 1.69
Residual
-23.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.